Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to share news the company has announced the first patient has been enrolled in ARCHER which is a Phase 2 double-blind, randomized, placebo-controlled trial of CardiolRX. Elsley telling Proactive, this study is designed to study the safety and tolerability of CardiolRX and to also see the impact on patients presenting with acute myocarditis.
Cardiol Therapeutics hits major milestone with first patient enrolled in Phase 2 trial of CardiolRX
